home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Organon & Co. Common Stock (NY:OGN)

6.340 -0.010 (-0.16%)

Official Closing Price Updated: 7:00 PM EDT, Mar 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Organon & Co. Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

18 19 Next >

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

October 28, 2024

From Organon & Co.

Via Business Wire

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

October 28, 2024

The acquisition expands Organon’s dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S.

From Roivant Sciences

Via GlobeNewswire

Want $300 in Dividends Every Month? Invest $20,000 in Each of These 3 Stocks ↗

October 24, 2024

These dividend stocks all pay yields of around 6% and higher.

Via The Motley Fool

P/E Ratio Insights for Organon ↗

October 02, 2024

Via Benzinga

3 Cheap High Dividend Stocks For Passive Income ↗

August 30, 2024

These undervalued high yield stocks could return over 10% per year.

Via Talk Markets

High Dividend 50: Organon & Co. ↗

June 27, 2024

Organon & Co.’s current annual dividend is $1.12 per share. At around $20 per share, Organon stock has a high yield of 5.4%.

Via Talk Markets

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4 ↗

October 22, 2024

Via Benzinga

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗

October 21, 2024

Via Benzinga

Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024

October 09, 2024

From Organon & Co.

Via Business Wire

Organon, Howmet Aerospace And More: CNBC's 'Final Trades' ↗

October 03, 2024

On CNBC's "Halftime Report Final Trades," Stephen Weiss of Short Hills Capital Partners named ProShares Short QQQ as his final trade.

Via Benzinga

Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11

September 30, 2024

From Organon & Co.

Via Business Wire

Week In Review: Nippon Shinyaku Signs $735 Million Deal For DMD Therapy ↗

September 21, 2024

Japan’s Nippon Shinyaku will acquire European rights for a Duchenne muscular dystrophy disease therapy developed by Capricor Therapeutics of San Diego. Nippon Shinyaku will pay $20 million upfront and...

Via Talk Markets

Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B ↗

September 18, 2024

Organon is set to acquire Roivant Sciences' Dermavant Sciences, known for developing immuno-dermatology treatments, including FDA-approved Vtama cream for plaque psoriasis. The deal, valued up to $1.2...

Via Benzinga

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

September 18, 2024

From Organon & Co.

Via Business Wire

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

September 18, 2024

From Roivant Sciences

Via GlobeNewswire

JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability ↗

September 06, 2024

JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris.

Via Benzinga

Organon Stock Sees Relative Strength Rating Rise To 91 ↗

August 27, 2024

On Tuesday, Organon[ stock hit an key technical milestone, seeing its Relative Strength Rating jump to 91, up from 88 the day before.

Via Investor's Business Daily

Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold ↗

August 20, 2024

On Tuesday, generic drug maker Organon stock had its Relative Strength (RS) Rating upgraded to 83, up from 78 a day earlier.

Via Investor's Business Daily

Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets

August 20, 2024

From Organon & Co.

Via Business Wire

OGN Stock Earnings: Organon Beats EPS, Misses Revenue for Q2 2024 ↗

August 06, 2024

OGN stock results show that Organon beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

Via InvestorPlace

Organon Reports Results for the Second Quarter Ended June 30, 2024

August 06, 2024

From Organon & Co.

Via Business Wire

Jim Cramer Says No To This Health Care Stock, Recommends Holding On To Constellation Energy: 'It's Up A Huge Amount' ↗

July 30, 2024

Jim Cramer said Constellation Energy is a "solar play that is a very good company. It's up a huge amount versus a lot of other stocks."

Via Benzinga

Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024

July 09, 2024

From Organon & Co.

Via Business Wire

3 High-Yield Dividend ETFs to Buy to Generate Passive Income ↗

July 06, 2024

These exchange-traded funds should keep the income flowing in regularly.

Via The Motley Fool

Topics ETFs

Value Investing Is Back! 3 Stocks With Strong Fundamentals to Buy Now ↗

June 26, 2024

Uncover three top value stocks to buy with robust fundamentals for stable long-term growth amid turbulence.

Via InvestorPlace

3 Stocks With Mouthwatering Dividends You Can Buy Right Now ↗

June 08, 2024

These stocks offer great dividends and more.

Via The Motley Fool

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14

May 24, 2024

From Organon & Co.

Via Business Wire

Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 5% Dividend Yields ↗

May 10, 2024

Via Benzinga

Organon Announces Pricing of $1.0 Billion Senior Notes Offering

May 07, 2024

From Organon & Co.

Via Business Wire

Organon Announces Proposed $1.0 Billion Senior Notes Offering

May 07, 2024

From Organon & Co.

Via Business Wire

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com